Belkin Launches Kid-sized Comfort and High-quality Sound With the SoundForm Inspire Headset for Kids
31.8.2023 19:00:00 EEST | Business Wire | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced the SoundForm Inspire Over-Ear Headset for Kids, a premium over-ear headset with built-in boom mic and 35 hours of battery life, designed just for kids.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831308540/en/
SoundForm Inspire Kids Headphones (Photo: Business Wire)
The SoundForm Inspire is creatively engineered for children to listen safely and comfortably while learning and playing. The headset is built with 40mm drivers to deliver Belkin Signature Sound, and a volume cap of 85 decibels to protect young ears. The soft, adjustable headband folds up for portability, and smaller ear cups provide an excellent fit for kids’ ears. RockStar Mode features an additional 3.5mm output port that lets kids share audio content with a classmate or friend. A quality boom mic keeps the sound clear during distance learning, with an indicator light to tell when the headset is on mute. It is available in black and lavender colors.
Product features:
- Belkin Signature Sound with 40mm drivers for clean and clear audio, tuned specifically for kids
- 35 hours of battery life for extended playtime
- 85dB volume limiter to protect hearing
- 3.5mm input port to connect to laptops, tablets, infotainment systems, phones, and other devices
- RockStar Mode allows audio sharing with additional 3.5mm output port
- High-quality flip-up boom microphone to be heard on calls and games
- Mute button and LED mute indicator for easily monitoring kids’ activity
- Bluetooth 5.2 connects easily to devices within 30 feet for wireless connection
- USB-C port for fast charging and wired audio input
- Foldable, extendable, and comfortable over-ear design for comfort and convenience
- Product housing is made with minimum of 23% post-consumer recycled plastics
- 100% plastic-free packaging
Belkin Kids collection includes the new SoundForm Inspire Over-Ear Headset, SoundForm Nano Wireless Earbuds and SoundForm Mini On-Ear Headphones.
The SoundForm Inspire is available to order now for $39.99 USD at Belkin.com and coming soon to Amazon.com and select major retailers worldwide.
Media kit is available for download HERE.
About Belkin
Belkin is an accessories market leader delivering power, protection, productivity, connectivity, audio, security, and home automation solutions for a broad range of consumer electronics and enterprise environments over the last 40 years. Designed in Southern California and sold in more than 100 countries around the world, Belkin creates products that empower people to get more life out of every single day whether at home, at work, or on a new adventure. In 2018 Belkin International merged with Foxconn Interconnect Technology to bolster its global influence while maintaining its steadfast focus on research and development, community, education and sustainability. Belkin remains forever inspired by people and the planet we live on.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831308540/en/
Contact information
For Media Inquiries:
Jen Wei
VP of Global Communications and Corporate Development
Comms@belkin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom